The Fetal and Neonatal Care Equipment Market Size was valued at USD 8.38 Billion in 2023. The global fetal and neonatal care equipment industry is projected to grow from USD 9.12 Billion in 2024 to USD 16.57 Billion by 2032, exhibiting a CAGR of 6.86% during the forecast period (2024 - 2032).
In February 2024, Hikma Pharmaceuticals PLC, a worldwide pharmaceutical corporation, declares the introduction of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the United States. COMBOGESIC® IV is a pain treatment medication administered intravenously. It is a mixture of 1,000 mg of acetaminophen and 300 mg of ibuprofen, which is a nonsteroidal anti-inflammatory drug (NSAID) and does not contain opioids. In October 2023, the US FDA granted approval for the use of this medication in people when it is essential to administer it intravenously.
It is indicated for two purposes: (i) to alleviate mild to moderate pain, and (ii) to assist in managing moderate to severe pain when used alongside opioid analgesics. The American Society of Anesthesiology (ASA) emphasizes the significance of a multimodal strategy to pain management. This method involves using various interventions with diverse mechanisms of action. These interventions may have additive or synergistic effects, which can help optimize pain relief. COMBOGESIC® IV provides healthcare providers with a novel method of pain management that does not involve opioids. It achieves this by combining active pharmacological components with distinct modes of action into a single formulation.
In May 2024, Natera, Inc., a prominent company in the field of cell-free DNA (cfDNA) and genetic testing, introduced a novel fetal RhD diagnostic that utilizes cfDNA. At a crucial moment for the healthcare sector, this is assisting physicians in managing patient care amidst the widespread scarcity of Rho(D) immune globulin treatment (RhIg).
Natera's test can be conducted as early as nine weeks of pregnancy and identifies the RhD status of the fetus using the pregnant patient's blood. This includes detecting complicated pseudogene and RhD-CE-D hybrid variants. Most other NIPT laboratories do not provide fetal RhD testing, which sets Natera apart due to its fundamental SNP-based technique. Approximately 15 percent of pregnant individuals have a negative RhD blood type. When the mother's blood type is RhD-negative and the baby's blood type is RhD-positive, the mother's immune system can produce antibodies (alloimmunization) that may cause hemolytic illness in the fetus and infant.
Various factors, for example, public and private drives to help patient consideration and rising number of neonatal consideration offices around the world are liable for development of the fetal and neonatal consideration gear market during the figure time frame.
Besides, new-conceived screening programs offer a ton of advantages which emphatically influences the market development. State run administrations of various topographical areas are taking up a ton of drives and bringing issues to light about new-conceived screening and its advantages.
Different government and non-government associations are effectively centered around offering better fetal and maternal consideration choices. For instance, in June 2018, the American Society of Hematology (ASH) drove a mission to battle sickle cell infection in Africa and encouraged legislatures, especially in Sub-Saharan Africa, to put resources into the new-conceived screening of the illness.
Then again, developing inclination for renovated gadgets across creating economies might hamper the development of the market.
The fetal and neonatal care equipment market has been segmented into type, product, and end user.
By type, the fetal and neonatal care equipment market has been segmented into fetal monitors, fetal pulse oximeters, fetal ultrasound devices, fetal MRI systems, and fetal doppler devices. Fetal monitors segment is further segmented into antepartum fetal monitors and intrapartum fetal monitors.
Based on product, the fetal and neonatal care equipment market has been segmented into Infant warmers, neonatal phototherapy equipment, neonatal incubators, convertible warmers & incubators, respiratory care devices, neonatal monitoring devices, and neonatal diagnostic imaging devices. Infant warmers segment is further segmented into electric warmers and non-electric warmers. Neonatal phototherapy equipment segment is further segmented into conventional phototherapy and fiber-optic phototherapy. Respiratory care devices segment is further segment into neonatal ventilators, continuous positive airway pressure devices, and resuscitators, and others. Neonatal monitoring devices segment are further segmented into blood pressure monitors, cardiac monitors, pulse oximeters, capnographs, extracorporeal membrane oxygenation systems, and integrated monitoring devices. Neonatal diagnostic imaging devices segment is further segmented into ultrasound systems, X-ray imaging systems, and others.
The market, by end user, has been segmented into hospitals & clinics, fertility centres, and others.
The global fetal and neonatal care equipment global market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The fetal and neonatal care equipment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European fetal and neonatal care equipment global market has been segmented into Western Europe and Eastern Europe. The Western Europe fetal and neonatal care equipment market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The fetal and neonatal care equipment global market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fetal and neonatal care equipment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global fetal and neonatal care equipment market owing to the high domestic income, and presence of major market players. Increasing neonatal population is a major factor driving the growth of the new-born screening market. According to data published by the Centers for Disease Control and Prevention in January 2017, there were 3,945,875 births in the US in 2017. This means the birth rate in the US in 2017 was 12.2 per 1000 population.
Europe is expected to hold the second largest position in the global fetal and neonatal care equipment market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The fetal and neonatal care equipment market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing birth rate and growing focus of major market players in the region.
The Middle East & Africa has the lowest share of the fetal and neonatal care equipment global market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Recent Development
In May 2024: Natera, Inc., a prominent company in the field of cell-free DNA (cfDNA) and genetic testing, introduced a novel fetal RhD diagnostic that utilizes cfDNA. At a crucial moment for the healthcare sector, this is assisting physicians in managing patient care amidst the widespread scarcity of Rho(D) immune globulin treatment (RhIg). Natera's test can be conducted as early as nine weeks of pregnancy and identifies the RhD status of the fetus using the pregnant patient's blood. This includes detecting complicated pseudogene and RhD-CE-D hybrid variants. Most other NIPT laboratories do not provide fetal RhD testing, which sets Natera apart due to its fundamental SNP-based technique. Approximately 15 percent of pregnant individuals have a negative RhD blood type. When the mother's blood type is RhD-negative and the baby's blood type is RhD-positive, the mother's immune system can produce antibodies (alloimmunization) that may cause hemolytic illness in the fetus and infant.
In February 2024: Hikma Pharmaceuticals PLC, a worldwide pharmaceutical corporation, declares the introduction of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the United States. COMBOGESIC® IV is a pain treatment medication administered intravenously. It is a mixture of 1,000 mg of acetaminophen and 300 mg of ibuprofen, which is a nonsteroidal anti-inflammatory drug (NSAID) and does not contain opioids.
In October 2023: The US FDA granted approval for the use of this medication in people when it is essential to administer it intravenously. It is indicated for two purposes: (i) to alleviate mild to moderate pain, and (ii) to assist in managing moderate to severe pain when used alongside opioid analgesics. The American Society of Anesthesiology (ASA) emphasizes the significance of a multimodal strategy to pain management. This method involves using various interventions with diverse mechanisms of action. These interventions may have additive or synergistic effects, which can help optimize pain relief. COMBOGESIC® IV provides healthcare providers with a novel method of pain management that does not involve opioids. It achieves this by combining active pharmacological components with distinct modes of action into a single formulation.
In March 2022: Butterfly Network, Inc., an advanced wellbeing organization changing consideration with handheld, entire body ultrasound has gotten an award in how much USD 5 million from the Bill and Melinda Gates Foundation to work on maternal and fetal wellbeing. Through this award Butterfly will give 1,000 medical services laborers in Sub-Saharan Africa with Butterfly iQ+, the world's just handheld, entire body point-of-care ultrasound test.
In February 2022: Philips has extended its ultrasound portfolio with cutting edge hemodynamic appraisal and estimation abilities on its handheld place of-care ultrasound - Lumify with the expansion of Pulse Wave Doppler to empowering clinicians to evaluate blood stream in a wide scope of reason behind care demonstrative applications including cardiology, vascular, stomach, urology, obstetrics and gynecology.
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â 2032: USD 16.57 Billion |
| Â Â CAGR | Â Â 6.86%: 2024-2032 |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2024-2032 |
| Â Â Historical Data | Â Â 2022 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Product, and End user |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
|   Key Vendors |   Fisher & Paykel Healthcare Limited, Natus Medical Incorporated, Philips Healthcare, Phoenix Medical Systems Pvt. Ltd., Toitu Co., Ltd., GE Healthcare, Masimo Corporation, Medtronic PLC, Arjo, Atom Medical Corporation, Cardinal Health, Drägerwerk AG & Co. KGaA, Edan Instruments, Inc., Utah Medical Products, Inc., Vyaire Medical Inc., Others |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Public and private initiatives to support patient care · Rising number of neonatal care facilities |
Fetal Neonatal Care Equipment Market Highlights:
Frequently Asked Questions (FAQ) :
The Fetal and neonatal care equipment market was valued at USD 16.57 Billion in 2032.
The Fetal and neonatal care equipment market is expected to exhibit a solid 6.86% CAGR over the forecast period.
Growing awareness about the importance of fetal and neonatal care in terms of preventing child mortality is the major driver for the Fetal and neonatal care equipment market.
The Americas and Europe dominate the global fetal and neonatal care equipment market.
Leading players in the fetal and neonatal care equipment market include Fisher & Paykel, Toitu, Philips, Natus Medical, and Medtronic, among others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
